Jianmin Pharmaceutical Group Co Ltd

SHG:600976 China Drug Manufacturers - Specialty & Generic
Market Cap
$664.63 Million
CN¥4.88 Billion CNY
Market Cap Rank
#10567 Global
#2365 in China
Share Price
CN¥31.79
Change (1 day)
+0.79%
52-Week Range
CN¥31.13 - CN¥47.65
All Time High
CN¥83.88
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Jianmin Pharmaceutical Group Co.,Ltd. manufactures and sells medicines in China. It provides medicines and pediatric drugs under the Jianmin, Longmu, and Yekaitai brand name. The company provides OTC, medical, and general health products, as well as consultation service. Jianmin Pharmaceutical Group Co.,Ltd. was founded in 1993 and is headquartered in Wuhan, China.

Jianmin Pharmaceutical Group Co Ltd (600976) - Net Assets

Latest net assets as of September 2025: CN¥2.60 Billion CNY

Based on the latest financial reports, Jianmin Pharmaceutical Group Co Ltd (600976) has net assets worth CN¥2.60 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.34 Billion) and total liabilities (CN¥1.74 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥2.60 Billion
% of Total Assets 59.95%
Annual Growth Rate 10.76%
5-Year Change 85.17%
10-Year Change 145.68%
Growth Volatility 28.33

Jianmin Pharmaceutical Group Co Ltd - Net Assets Trend (2001–2024)

This chart illustrates how Jianmin Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Jianmin Pharmaceutical Group Co Ltd (2001–2024)

The table below shows the annual net assets of Jianmin Pharmaceutical Group Co Ltd from 2001 to 2024.

Year Net Assets Change
2024-12-31 CN¥2.45 Billion +8.59%
2023-12-31 CN¥2.26 Billion +20.81%
2022-12-31 CN¥1.87 Billion +19.10%
2021-12-31 CN¥1.57 Billion +18.51%
2020-12-31 CN¥1.32 Billion +9.55%
2019-12-31 CN¥1.21 Billion +5.49%
2018-12-31 CN¥1.15 Billion +3.40%
2017-12-31 CN¥1.11 Billion +7.38%
2016-12-31 CN¥1.03 Billion +3.41%
2015-12-31 CN¥997.36 Million -0.47%
2014-12-31 CN¥1.00 Billion +6.55%
2013-12-31 CN¥940.46 Million +4.14%
2012-12-31 CN¥903.10 Million +2.98%
2011-12-31 CN¥876.97 Million +3.32%
2010-12-31 CN¥848.81 Million +3.47%
2009-12-31 CN¥820.32 Million +7.76%
2008-12-31 CN¥761.24 Million +2.51%
2007-12-31 CN¥742.63 Million -3.13%
2006-12-31 CN¥766.61 Million +0.92%
2005-12-31 CN¥759.65 Million +7.73%
2004-12-31 CN¥705.12 Million +142.88%
2003-12-31 CN¥290.32 Million +11.43%
2002-12-31 CN¥260.54 Million +11.55%
2001-12-31 CN¥233.57 Million --

Equity Component Analysis

This analysis shows how different components contribute to Jianmin Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 2050.7% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥1.61 Billion 66.19%
Common Stock CN¥153.40 Million 6.30%
Other Comprehensive Income CN¥168.00 Million 6.90%
Other Components CN¥502.06 Million 20.62%
Total Equity CN¥2.44 Billion 100.00%

Jianmin Pharmaceutical Group Co Ltd Competitors by Market Cap

The table below lists competitors of Jianmin Pharmaceutical Group Co Ltd ranked by their market capitalization.

Company Market Cap
Sanxiang Co Ltd
SHE:000863
 		$471.17 Million
Jupiter Wagons Limited
NSE:JWL
 		$471.39 Million
Central Plaza Hotel Public Company Limited
BK:CENTEL
 		$471.57 Million
Zhejiang Yongjin Metal Technology Co Ltd
SHG:603995
 		$471.63 Million
Klöckner & Co SE
PINK:KLKNF
 		$471.12 Million
Jilin Yatai Group Co Ltd
SHG:600881
 		$470.97 Million
INVESTIS HOLDING SF-,10
F:IYP
 		$470.95 Million
Regulus Therapeutics Inc
NASDAQ:RGLS
 		$470.59 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Jianmin Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 2,247,706,068 to 2,435,305,586, a change of 187,599,518 (8.3%).
  • Net income of 362,178,656 contributed positively to equity growth.
  • Dividend payments of 187,718,217 reduced retained earnings.
  • Other comprehensive income increased equity by 167,999,880.
  • Other factors decreased equity by 154,860,801.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥362.18 Million +14.87%
Dividends Paid CN¥187.72 Million -7.71%
Other Comprehensive Income CN¥168.00 Million +6.9%
Other Changes CN¥-154.86 Million -6.36%
Total Change CN¥- 8.35%

Book Value vs Market Value Analysis

This analysis compares Jianmin Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.99x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 22.85x to 1.99x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2001-12-31 CN¥1.39 CN¥31.79 x
2002-12-31 CN¥1.51 CN¥31.79 x
2003-12-31 CN¥1.46 CN¥31.79 x
2004-12-31 CN¥3.75 CN¥31.79 x
2005-12-31 CN¥3.86 CN¥31.79 x
2006-12-31 CN¥4.49 CN¥31.79 x
2007-12-31 CN¥4.30 CN¥31.79 x
2008-12-31 CN¥4.89 CN¥31.79 x
2009-12-31 CN¥5.09 CN¥31.79 x
2010-12-31 CN¥5.39 CN¥31.79 x
2011-12-31 CN¥5.56 CN¥31.79 x
2012-12-31 CN¥5.73 CN¥31.79 x
2013-12-31 CN¥6.00 CN¥31.79 x
2014-12-31 CN¥6.37 CN¥31.79 x
2015-12-31 CN¥6.42 CN¥31.79 x
2016-12-31 CN¥6.59 CN¥31.79 x
2017-12-31 CN¥7.08 CN¥31.79 x
2018-12-31 CN¥7.44 CN¥31.79 x
2019-12-31 CN¥7.83 CN¥31.79 x
2020-12-31 CN¥8.59 CN¥31.79 x
2021-12-31 CN¥10.28 CN¥31.79 x
2022-12-31 CN¥12.22 CN¥31.79 x
2023-12-31 CN¥14.70 CN¥31.79 x
2024-12-31 CN¥16.00 CN¥31.79 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Jianmin Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 14.87%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 10.33%
  • • Asset Turnover: 0.82x
  • • Equity Multiplier: 1.76x
  • Recent ROE (14.87%) is above the historical average (9.44%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2001 9.93% 7.59% 0.72x 1.83x CN¥-142.79K
2002 10.43% 6.88% 0.79x 1.92x CN¥1.03 Million
2003 9.21% 5.65% 0.81x 2.02x CN¥-2.08 Million
2004 4.14% 5.28% 0.57x 1.37x CN¥-39.56 Million
2005 2.88% 2.20% 0.86x 1.52x CN¥-49.56 Million
2006 1.63% 0.89% 1.23x 1.50x CN¥-58.85 Million
2007 1.16% 0.80% 1.17x 1.24x CN¥-63.33 Million
2008 2.15% 1.89% 0.72x 1.58x CN¥-57.62 Million
2009 6.29% 3.19% 1.18x 1.67x CN¥-28.78 Million
2010 8.72% 4.56% 1.46x 1.31x CN¥-10.48 Million
2011 9.18% 5.54% 1.21x 1.37x CN¥-7.01 Million
2012 9.42% 5.35% 1.22x 1.44x CN¥-5.09 Million
2013 10.50% 4.81% 1.38x 1.58x CN¥4.60 Million
2014 11.93% 6.61% 1.13x 1.59x CN¥18.80 Million
2015 8.72% 3.75% 1.42x 1.63x CN¥-12.52 Million
2016 6.38% 2.74% 1.31x 1.78x CN¥-36.76 Million
2017 8.33% 3.35% 1.41x 1.77x CN¥-18.18 Million
2018 7.13% 3.76% 1.26x 1.51x CN¥-32.76 Million
2019 7.61% 4.09% 1.16x 1.61x CN¥-28.66 Million
2020 11.22% 6.02% 1.02x 1.84x CN¥16.10 Million
2021 19.55% 9.31% 1.16x 1.81x CN¥149.14 Million
2022 21.91% 11.21% 1.06x 1.85x CN¥221.79 Million
2023 23.20% 12.38% 1.01x 1.85x CN¥296.69 Million
2024 14.87% 10.33% 0.82x 1.76x CN¥118.65 Million

Industry Comparison

This section compares Jianmin Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $2,123,990,643
  • Average return on equity (ROE) among peers: -0.22%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Jianmin Pharmaceutical Group Co Ltd (600976) CN¥2.60 Billion 9.93% 0.67x $471.12 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078) $6.47 Billion 9.88% 3.77x $616.08 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $1.18 Billion 2.74% 0.95x $320.56 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $10.33 Billion 15.07% 0.27x $3.03 Billion
Wedge Industrial Co Ltd (000534) $298.72 Million 1.96% 0.38x $1.77 Billion
Yunnan Baiyao Group Co Ltd (000538) $35.11 Million 18.13% 0.80x $5.62 Billion
Hainan Haiyao Co Ltd (000566) $353.98 Million -9.58% 0.80x $702.18 Million
Tus Pharmaceutical Group Co Ltd (000590) $269.51 Million -61.02% 1.05x $317.08 Million
Northeast Pharmaceutical Group Co Ltd (000597) $927.49 Million 2.65% 1.38x $425.60 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $1.11 Billion 7.32% 0.29x $2.05 Billion
Renhe Pharmacy Co Ltd (000650) $261.49 Million 10.60% 0.82x $777.45 Million